Regel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regel

What Type of Medicine is Regel (Sucralfate)?

Regel is a prescription-only gastrointestinal agent primarily categorized as a Cytoprotective or Mucosal Protective Agent. This classification is key to understanding its function, as it focuses on protecting damaged tissue rather than solely neutralizing or suppressing acid production. Its active ingredient is Sucralfate, which is chemically defined as an aluminum salt of sucrose octasulfate, confirming its nature as a synthetic derivative based on the disaccharide sucrose. The medication is recognized as an antiulcer agent, and its characteristic is its local action with minimal systemic absorption.

Composition, Forms, and General Purpose

Regel is a single-ingredient product available for the oral route in both oral suspension and tablet forms. This availability in different dosage forms is relevant, as the liquid suspension is often preferred for ensuring comprehensive coverage of the upper digestive tract lining. The general purpose of Regel is to provide a physical, defensive shield against aggressive agents—like acid, pepsin, and bile salts—that naturally exist in the stomach environment.

Pharmacologically, Sucralfate's function is highly localized, with minimal absorption of the active compound into the bloodstream. By selectively binding to proteins exposed in ulcers, Regel creates an optimal local environment for the vulnerable gastrointestinal mucosa to heal and regenerate.

What side effects are possible with Regel?

Possible Side Effects and Safety Information

The official safety profile for Regel (Sucralfate) outlines adverse reactions reported during clinical trials and post-marketing surveillance. This information is classified by the body system affected and frequency, based on government regulatory documents.


Documented Adverse Reactions by System and Frequency

The most frequently reported adverse reaction in clinical trials was constipation, occurring in approximately 2% of patients. All other listed adverse effects observed in controlled studies were reported in less than 0.5% of patients.

System-Organ Class Reactions Reported (Infrequent)
Gastrointestinal Diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, vomiting
Nervous System Dizziness, headache, insomnia, sleepiness, vertigo
Dermatological Pruritus (itching), rash

Serious Adverse Reactions and Safety Considerations

The regulatory label documents several serious safety considerations reported primarily through post-marketing experience:

  • Bezoar Formation: Cases of physical intestinal blockage have been reported, primarily associated with underlying medical conditions that may cause delayed gastric emptying or concomitant enteral tube feedings.

  • Hypersensitivity: Severe post-marketing reports include hypersensitivity reactions such as anaphylactic reactions, laryngeal edema, and bronchospasm.

  • Aluminum Toxicity Risk: In patients with chronic renal failure or those undergoing dialysis, the small amounts of absorbed aluminum can accumulate. This accumulation is associated with the risk of aluminum toxicity, including osteodystrophy and encephalopathy, and this risk is heightened with long-term exposure.

  • Administration Safety Constraint: The oral suspension form of Sucralfate is for the oral route only. Fatal complications, specifically pulmonary and cerebral emboli, have been documented following the inappropriate intravenous administration of the oral suspension.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Regel (Sucralfate) overdose indicates a minimal risk for acute systemic toxicity. Due to the drug's limited absorption from the gastrointestinal tract, most cases of acute oral overdosage report that patients remained asymptomatic or experienced minor local gastrointestinal symptoms, such as abdominal pain or constipation. Management for acute excess ingestion is generally restricted to symptomatic and supportive treatment, as no specific antidote is known.

Serious Outcomes and Population Risk

A primary documented safety concern involves the potential for aluminum toxicity. The drug contains an aluminum salt, and its accumulation can lead to severe long-term outcomes, including aluminum osteodystrophy and encephalopathy. This risk is significantly higher in patients with chronic renal failure and the elderly who have impaired aluminum excretion, necessitating cautious use in these populations.

Required Emergency Actions

Immediate medical help must be sought if severe, unrelenting symptoms or any documented signs of aluminum toxicity are present. Regulatory sources direct users to call a Poison Control Helpline or emergency services immediately if the individual collapses, has a seizure, or is experiencing severe respiratory difficulty.

Therapeutic Uses of Regel

What Regel Treats: Main Uses and Benefits

Regel (Sucralfate) is generally used to treat and prevent ulcers in the intestines, and is commonly used across domains where additional symptomatic support is needed. Its core therapeutic application is focused on addressing symptoms related to inflammatory or irritative states throughout the digestive tract.


Promoting Healing and Symptomatic Relief

Regel is commonly used for the short-term treatment of conditions characterized by periods of heightened symptoms, including peptic ulcer disease (gastric and duodenal ulcers), gastritis, and Gastroesophageal Reflux Disease (GERD). Its primary benefit is to support tissue repair and generally helps ease the characteristic ulcer pain and recurrent burning sensations associated with active ulcers and inflammation.

This application is relevant in clinical settings that involve acute or unstable symptom patterns, such as the healing phase of ulcers or when patients experience disruptive episodes of dyspepsia, heartburn, or upper abdominal soreness. The application supports general well-being during symptomatic phases.

Quick Fact: Relief for Ulcer Pain and Gastric Discomfort


Localized Protection in High-Risk Scenarios

Regel is commonly used for its localized protective action in specific high-risk contexts where mucosal injury is a concern. This includes supportive symptomatic assistance for painful inflammation like oral mucositis or radiation proctitis, and is relevant when patients exposed to damaging agents like NSAIDs need protection; this generally supports the patient during difficult episodes by easing distress. The use of Regel in these scenarios assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Regel? Official Eligibility Information

Regel (Sucralfate) is officially intended for use in the adult population. Eligibility for this medicine is strictly defined by regulatory documents, listing absolute prohibitions and conditional restrictions.

Populations for Whom Use is Restricted or Prohibited

Classification Population/Condition Regulatory Status (Example)
Contraindicated Patients with known hypersensitivity to sucralfate or any excipients. Must not use
Conditional Use Patients with Chronic Renal Failure or those on Dialysis. Use with caution due to the risk of aluminum accumulation.
Conditional Use Patients with conditions predisposing to bezoar formation (e.g., delayed gastric emptying). Use with caution

Age and Physiological Status

  • Pediatric Patients: Safety and effectiveness have not been established in the pediatric population; use is generally not recommended.
  • Older Adults (Geriatrics): Caution is advised, reflecting the greater frequency of decreased renal function in this group.
  • Pregnancy: Classified as FDA Pregnancy Category B. Use is recommended only if clearly needed, as adequate human studies are unavailable.
  • Lactation: Caution should be exercised, as it is not known if the drug is excreted in human milk.

Connection to the Overall Eligibility Profile

The official eligibility profile is structured around excluding patients with a known allergy to the drug and placing strict limits on use in populations with impaired renal function due to the risk of aluminum retention. For all other groups, including pediatric patients, restrictions are primarily based on the lack of established safety and effectiveness data in government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Regel (Sucralfate) is primarily driven by its local, non-systemic action. Sucralfate is an aluminum salt that can bind to or chelate other substances within the gastrointestinal tract, leading to reduced absorption of co-administered oral medicines. This is classified as a pharmacokinetic interaction.

Documented Exposure-Modifying Interactions

Sucralfate reduces the extent of absorption (bioavailability), resulting in decreased plasma concentration (exposure) of several medicines, including Digoxin, Phenytoin, Levothyroxine, Cimetidine, Ranitidine, Quinidine, Theophylline, Ketoconazole, and Fluoroquinolone Antibiotics (such as Ciprofloxacin).

Interaction-Related Restrictions

To mitigate the risk of reduced exposure, regulatory documents require a mandatory timing separation: interacting oral medicines must be administered 2 hours before sucralfate. This procedural constraint is intended to ensure adequate systemic exposure of the co-administered drug.

Population-Specific Interaction Notes

Co-administration with other aluminum-containing antacids increases the total aluminum body burden. This is a specific concern for individuals with Chronic Renal Failure or Dialysis Patients, who are at heightened risk of aluminum accumulation and toxicity due to impaired excretion of the aluminum component. Therefore, its use is constrained in this population.

Mechanism of Action

Regel (Sucralfate) exerts its function through two distinct pharmacodynamic mechanisms: physical barrier formation and augmentation of local cytoprotective pathways.


Formation of a Selective Adhesive Barrier

The primary action of Regel is the acid-dependent polymerization of its active molecule into a viscous, adhesive gel. This gel develops a strong electrostatic affinity for the positively charged proteins exposed in an ulcer crater. By adhering selectively to damaged tissue, it forms a physical barrier that separates the mucosa from direct contact with corrosive gastric contents, including acid and bile salts.


Neutralization and Enzyme Inhibition

Beyond acting as a physical separator, the complex reduces the chemical degradation caused by aggressor molecules. The polyanionic structure effectively adsorbs bile salts and prevents the proteolytic enzyme pepsin from binding to its target substrates, leading to the inhibition of its destructive activity. This mechanism limits the ongoing chemical and enzymatic trauma, facilitating an environment conducive to cellular restitution.


Augmentation of Intrinsic Cytoprotection

Regel engages local biological pathways by stimulating local prostaglandin production, which enhances the secretion of mucus and bicarbonate ( HCO3^-). Furthermore, the drug binds and protects endogenous growth factors (like EGF) from degradation, concentrating them at the injury site. These actions enhance epithelial restitution and cell proliferation, contributing to the physiological process of tissue restoration.

Dosage and Administration Information

How to Use Regel: Official Administration Guidelines

Regel (Sucralfate) is officially administered exclusively via the oral route, available as a 1 gram tablet or a 1 gram per 10 milliliter oral suspension. The fundamental use pattern is structured around a precise time-relationship to meals to ensure the medicine can effectively coat the gastrointestinal lining.


Standard Dosing and Frequency

For the treatment of active duodenal ulcers, the standard dose is 1 gram taken four times a day (qid). This regimen is typically followed for a course duration of 4 to 8 weeks, unless healing is confirmed earlier. After the initial treatment phase, the usage pattern shifts to a lower maintenance dose of 1 gram taken only twice a day (bid). Continuation of this maintenance regimen is documented for periods up to 12 months.


Administration Conditions and Constraints

All doses of Regel must be administered on an empty stomach. This typically translates to taking the medicine one hour before meals and the final dose at bedtime. A critical procedural constraint requires that other antacids must not be taken within 30 minutes before or after a dose of Regel to prevent interference with its intended use. For the liquid formulation, the oral suspension must be shaken well prior to administration. Official labeling specifies that the oral suspension is strictly forbidden from being administered intravenously. Furthermore, guidelines advise that dosing for older adults should be cautious, often starting at the lower end of the established dosing range.

Recent Clinical Evidence

Recent Clinical Evidence

Core Evidence in Osteoarthritis

Studies have primarily examined the use of this substance—a non-steroidal anti-inflammatory drug (NSAID)—in participants diagnosed with osteoarthritis (OA). Research, including systematic reviews of randomized controlled trials (RCTs), has explored the assessment of parameters such as joint function and participant perception of pain in OA. Studies primarily examined the substance in the context of its influence on inflammation, the process associated with joint pain.

Reported data from these studies indicated differences in pain scores compared to baseline measurements for those receiving the substance. In trials spanning intervention periods, reported outcomes for the substance varied when compared to those for placebo. Research has also addressed physical function, using standardized assessment tools like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function subscale.


Combination Therapy Research

Clinical research has also examined regimens in which the substance was used alongside other common treatments for OA (such as acetaminophen or physical therapy). A few preliminary studies were designed to compare outcomes between a combination regimen and monotherapy (using only one treatment).

Evidence remains limited on the long-term observation of combination therapies involving this substance. It is not yet clear whether research observations from combined treatments differ significantly from those of single-agent treatment in relation to disease progression or quality of life, underscoring the need for more extensive studies.


Safety Data Overview

Studies have involved the assessment of adverse events and the substance's tolerability during short-term use. Data reported by researchers frequently detailed adverse events, including gastrointestinal symptoms (such as nausea and dyspepsia).

Specific research has also evaluated risk assessment in participants with certain pre-existing conditions. For example, individuals with pre-existing kidney conditions were often excluded from certain studies due to the known influence of NSAIDs on renal function. Study protocols included specific guidance on dosage, a factor which influenced the reported incidence of adverse cardiovascular events in those populations.

Frequently Asked Questions (FAQ)

Common questions about Regel (FAQ)


Q: Are there any known issues with taking Regel if you have a history of kidney problems?

A: The official product label advises caution for patients with severe kidney problems, such as chronic renal failure or those on dialysis. This is because Regel contains aluminum, and impaired kidney function can increase the risk of aluminum accumulating in the body. The official label notes that use in this population requires close attention and caution.


Q: What is the expected long-term safety profile of Regel in regulatory documents?

A: Regulatory documents indicate Regel is used for short-term treatment and maintenance therapy, which can last up to 12 months. Regulatory documents state that use in patients with chronic renal impairment is constrained and requires caution due to the risk of aluminum toxicity, which is a key long-term safety consideration for this population.


Q: How long does Regel stay in the body after the last use?

A: Studies confirm that Regel is only minimally absorbed from the gastrointestinal tract, meaning very little of the active substance enters the bloodstream. The small amount of aluminum that is absorbed is typically excreted quickly by individuals who have healthy kidney function.


Q: Can Regel be taken with common over-the-counter pain relievers like ibuprofen?

A: Official warnings state that Regel can reduce the absorption of many oral medicines by binding to them in the stomach. To minimize this potential interaction, official documents require a timing separation: administration of other oral medicines must be separated by two hours from Regel.


Q: Can Regel cause changes in mood or sleep patterns?

A: The official list of adverse reactions includes effects on the nervous system, such as insomnia (difficulty sleeping) and sleepiness. Changes in mood are not typically listed in the drug's official side effect profile. The description of side effects should be used as a basis for conversation with a healthcare provider.


Q: Are there any dietary restrictions or foods to avoid when using Regel?

A: The product's usage pattern requires it to be taken on an empty stomach, usually one hour before meals. There are no specific food groups restricted in the official label, but official guidelines specify that other antacids must not be taken within 30 minutes before or after a dose to prevent interference.


Q: How do the official sources describe the process of stopping Regel?

A: Regulatory documents define the duration of treatment, which includes an initial short course followed by a longer maintenance phase to prevent recurrence of ulcers. The official information does not describe a specific procedure for tapering or stopping the drug entirely, as the decision is typically made by a healthcare provider.


Q: What is the documented rate of the most serious adverse effects in clinical trials?

A: The most frequently reported side effect in clinical trials was constipation, occurring in approximately 2% of patients. More serious safety events, like severe allergic reactions or physical intestinal blockage (bezoar formation), are reported primarily through post-marketing surveillance, which does not provide a standard rate from controlled clinical trials.


Q: How quickly should someone expect to notice the effects of Regel?

A: The product is indicated for the short-term treatment of active ulcers over a course of up to eight weeks. Clinical trials observed initial healing occurring in some participants during the first couple of weeks of use, which results from the drug's local protective action.


Q: What kind of studies or research back up the use of Regel?

A: The regulatory approval of Regel for the treatment of active duodenal ulcers is supported by controlled clinical trials. Studies indicated that the drug was observed to be superior to a placebo in promoting ulcer healing by selectively adhering to the ulcer site.


Q: Can Regel interfere with the effectiveness of birth control pills?

A: Because Regel can reduce the absorption of many oral medicines, the effectiveness of co-administered drugs may be affected. Although birth control pills are not specifically listed on the label, official documents advise a timing separation of two hours between Regel and other oral medicines to ensure adequate absorption.


Q: Is Regel listed as a controlled substance or does it have potential for abuse?

A: The active ingredient in Regel, sucralfate, is not classified as a controlled substance by regulatory authorities. It is designated as a prescription-only medication.


Q: What happens if a dose of Regel is accidentally missed?

A: Official patient information provides specific guidance on how to proceed if a dose is missed. This guidance focuses on following the regular dosing pattern and avoiding a double dose.


Q: Does Regel have any interactions with common herbal supplements like St. John's Wort?

A: The official drug label does not specifically name St. John's Wort or other herbal supplements. However, Caution is noted in regulatory information for all co-administered oral products, including herbal supplements, due to the drug’s potential to reduce absorption.


Q: Can people with a documented allergy to a specific drug class still take Regel?

A: Regel is officially contraindicated only for patients who have a known hypersensitivity or allergy to the active substance, sucralfate, or any of the inactive ingredients (excipients). There are no specific warnings related to cross-reactivity with other drug classes listed on the product label.


Q: Is the effect of Regel permanent or does the condition return after stopping it?

A: Regel is indicated for the healing of active ulcers and for maintenance therapy to help prevent their recurrence. The drug facilitates the healing process, but official information does not claim that the drug provides a permanent curative effect after treatment is stopped.


Q: Does alcohol interact negatively with Regel, and if so, how is it described?

A: Official drug labels generally do not list alcohol as a direct drug-drug interaction with Regel. The drug's official purpose is to protect the gastrointestinal lining from irritants.


Q: What makes Regel different from a placebo in clinical trials?

A: Clinical trials demonstrated that Regel was more successful than a placebo in the healing of duodenal ulcers. The observed efficacy difference supports its regulatory approval.


Q: Why is it recommended to check with a doctor before taking Regel with vitamins?

A: The official product information includes a warning that Regel may reduce the absorption of many orally administered products. The reason for this warning is that this mechanism extends to mineral and vitamin supplements.


Q: Is it okay to take Regel if I have mild asthma or other breathing issues?

A: One serious, though rare, adverse reaction reported after the drug was marketed is bronchospasm, which is a narrowing of the airways and part of a severe allergic reaction. The presence of bronchospasm as a reported adverse event is included in the safety information.


Q: Is Regel classified as a blood thinner or does it affect clotting?

A: Regel is classified as a cytoprotective antiulcer agent. Its mechanism is localized to the gastrointestinal tract, and it is not classified as a blood thinner and does not directly affect the blood clotting process.


Q: Can people with diabetes safely use Regel?

A: Official information indicates that co-administration may require regular monitoring of blood sugar. This is because a healthcare provider may need to adjust the dose of a patient’s diabetes medication based on the monitored blood sugar levels.


Q: Does Regel affect fertility or reproductive health, based on animal or human studies?

A: Nonclinical studies conducted in animals showed no negative effect on fertility in either male or female rats. There are currently no adequate human studies available regarding the drug's potential effects on human fertility or reproductive health.


Q: Are there known risks associated with combining Regel with herbal weight loss products?

A: Regel is known to reduce the absorption of many oral medicines due to a binding mechanism in the gut. Regulatory information includes a general warning regarding reduced absorption of any co-administered oral product, which would include herbal weight loss supplements.


Q: What is the difference between the immediate-release and extended-release forms of Regel?

A: Regel is officially available in two formats: a tablet and an oral suspension (liquid). The official product label does not mention or specify immediate-release or extended-release forms of the medication.


Q: Is there any official information on generic versions of Regel?

A: The active ingredient, sucralfate, is commonly available as a generic drug in the United States and various other markets, providing a general alternative to the branded product, Regel.

How should Regel be stored and disposed of?

How to Store and Dispose of Regel?

Regel must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). To protect the medicine from moisture and degradation, it is essential to keep the container tightly closed and store it in the original container. Excursions in temperature are generally permitted between 15 C and 30 C (59 F and 86 F).

For safety, this medication must always be stored out of the sight and reach of children and pets. Proper disposal is required for any unused or expired Regel. Do not dispose of this medicine by pouring it down a sink or flushing it down a toilet. Follow the specific instructions provided on the drug labeling or patient information, or utilize an official drug take-back program if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Regel found in:

A-Z Index: